Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792905 | 0.87 | PRKCA (0.35) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL10283237 | 0.81 | PRKCA (0.48) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL12429439 | 0.81 | KCNH2 (0.41) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL804489 | 0.79 | KCNH2 (0.32) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL10283255 | 0.78 | PRKCA (0.39) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL792664 | 0.76 | CNR2 (0.34) | NR1I2SCN9A | |
| SCHEMBL792730 | 0.75 | KCNH2 (0.31) | KCNH2NR1I2 | |
| SCHEMBL793024 | 0.70 | PRKCA (0.34) | KCNH2NR1I2PRKCAMMP12SCN9A | |
| SCHEMBL792918 | 0.70 | NR1I2 (0.36) | KCNH2NR1I2CYP3A4SCN5APRKCA | |
| SCHEMBL792811 | 0.70 | MTNR1A (0.40) | PRKCAMMP12SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | KCNH2 3813/4885NR1I2 1189/4885CYP3A4 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.